Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.

Proceedings of the National Academy of Sciences of the United States of America - 10 Jun 2025

Pappas Kyrie, Ferrari Matteo, Smith Perianne, Nandakumar Subhiksha, Khan Zahra, Young Serina B, LaClair Justin, Russo Marco Vincenzo, Huang-Hobbs Emmet, Schultz Nikolaus, Abida Wassim, Karthaus Wouter, Jasin Maria, L Sawyers Charles

Abstract excerpt

Recent approvals of polymeric adenosine diphosphate ribose (poly(ADP-ribose) polymerase inhibitors (PARPi) for BRCA-mutant metastatic castration resistant prostate cancer necessitate an understanding of the factors that shape sensitivity and resistance. Reversion mutations that restore homologous recombination (HR) repair are detected in ~50 to 80% of BRCA-mutant patients who respond but subsequently relapse, but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Cell Cycle Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Replication

Share to Drug Resistance, Neoplasm

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 40460119
DOI: 10.1073/pnas.2426743122
PMCID: PMC12167974

Genes

CDT1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.PMID 40460119Read ↗

BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complexSemantic proximity Read ↗

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsSemantic proximity Read ↗

Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.Semantic proximity Read ↗

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications.Semantic proximity Read ↗

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapySemantic proximity Read ↗

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.Semantic proximity Read ↗

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read ↗

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read ↗

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read ↗

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsSemantic proximity Read ↗

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired ResistanceSemantic proximity Read ↗

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.